View in EDS

Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC.

Saved in:
Bibliographic Details
Title: Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC.
Authors: Paz-Ares L; Hospital Universitario 12 de Octubre & Universidad Complutense, Madrid, Spain. Electronic address: lpazaresr@seom.org., Veillon R; CHU Bordeaux, Service des Maladies Respiratoires, Bordeaux, France., Majem M; Hospital de la Santa Creu I Sant Pau, Barcelona, Spain., Zhou C; Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China., Tang KJ; Division of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China., Kim SW; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Richardson G; Cabrini Medical Centre, Malvern, Australia., Girard N; Institut du Thorax Curie-Montsouris, Paris and Paris-Saclay University, UVSQ, Versailles, France., Sanborn RE; Earle A. Chiles Research Institute, Providence Cancer Institute of Oregon, Portland, OR, USA., Mansfield AS; Mayo Clinic, Rochester, MN, USA., Park K; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Schuchard J; Johnson & Johnson, Horsham, PA, USA., Diels J; Johnson & Johnson, Beerse, Belgium., Sermon J; Johnson & Johnson, Beerse, Belgium., Bhattacharya A; Johnson & Johnson, High Wycombe, UK., Lorenzini P; Johnson & Johnson, Spring House, PA, USA., Wortman-Vayn H; Johnson & Johnson, Raritan, NJ, USA., Knoblauch RE; Johnson & Johnson, Spring House, PA, USA., Agrawal T; Johnson & Johnson, Spring House, PA, USA., Baig M; Johnson & Johnson, Raritan, NJ, USA., Ono A; Shizuoka Cancer Center, Shizuoka, Japan., Sabari JK; NYU Langone Health, New York, NY, USA.
Source: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2026 Mar; Vol. 213, pp. 108788. Date of Electronic Publication: 2025 Oct 03.
Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III
Journal Info: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41671629
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Paz-Ares+L%22">Paz-Ares L</searchLink>; Hospital Universitario 12 de Octubre & Universidad Complutense, Madrid, Spain. Electronic address: lpazaresr@seom.org.<br /><searchLink fieldCode="AU" term="%22Veillon+R%22">Veillon R</searchLink>; CHU Bordeaux, Service des Maladies Respiratoires, Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Majem+M%22">Majem M</searchLink>; Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Zhou+C%22">Zhou C</searchLink>; Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Tang+KJ%22">Tang KJ</searchLink>; Division of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Kim+SW%22">Kim SW</searchLink>; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Richardson+G%22">Richardson G</searchLink>; Cabrini Medical Centre, Malvern, Australia.<br /><searchLink fieldCode="AU" term="%22Girard+N%22">Girard N</searchLink>; Institut du Thorax Curie-Montsouris, Paris and Paris-Saclay University, UVSQ, Versailles, France.<br /><searchLink fieldCode="AU" term="%22Sanborn+RE%22">Sanborn RE</searchLink>; Earle A. Chiles Research Institute, Providence Cancer Institute of Oregon, Portland, OR, USA.<br /><searchLink fieldCode="AU" term="%22Mansfield+AS%22">Mansfield AS</searchLink>; Mayo Clinic, Rochester, MN, USA.<br /><searchLink fieldCode="AU" term="%22Park+K%22">Park K</searchLink>; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Schuchard+J%22">Schuchard J</searchLink>; Johnson & Johnson, Horsham, PA, USA.<br /><searchLink fieldCode="AU" term="%22Diels+J%22">Diels J</searchLink>; Johnson & Johnson, Beerse, Belgium.<br /><searchLink fieldCode="AU" term="%22Sermon+J%22">Sermon J</searchLink>; Johnson & Johnson, Beerse, Belgium.<br /><searchLink fieldCode="AU" term="%22Bhattacharya+A%22">Bhattacharya A</searchLink>; Johnson & Johnson, High Wycombe, UK.<br /><searchLink fieldCode="AU" term="%22Lorenzini+P%22">Lorenzini P</searchLink>; Johnson & Johnson, Spring House, PA, USA.<br /><searchLink fieldCode="AU" term="%22Wortman-Vayn+H%22">Wortman-Vayn H</searchLink>; Johnson & Johnson, Raritan, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Knoblauch+RE%22">Knoblauch RE</searchLink>; Johnson & Johnson, Spring House, PA, USA.<br /><searchLink fieldCode="AU" term="%22Agrawal+T%22">Agrawal T</searchLink>; Johnson & Johnson, Spring House, PA, USA.<br /><searchLink fieldCode="AU" term="%22Baig+M%22">Baig M</searchLink>; Johnson & Johnson, Raritan, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Ono+A%22">Ono A</searchLink>; Shizuoka Cancer Center, Shizuoka, Japan.<br /><searchLink fieldCode="AU" term="%22Sabari+JK%22">Sabari JK</searchLink>; NYU Langone Health, New York, NY, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228800805%22">Lung cancer (Amsterdam, Netherlands)</searchLink> [Lung Cancer] 2026 Mar; Vol. 213, pp. 108788. <i>Date of Electronic Publication: </i>2025 Oct 03.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Scientific+Publishers%22">Elsevier Scientific Publishers </searchLink><i>Country of Publication: </i>Ireland <i>NLM ID: </i>8800805 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1872-8332 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201695002%22">01695002 </searchLink><i>NLM ISO Abbreviation: </i>Lung Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41671629
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.lungcan.2025.108788
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 108788
    Titles:
      – TitleFull: Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Paz-Ares L
      – PersonEntity:
          Name:
            NameFull: Veillon R
      – PersonEntity:
          Name:
            NameFull: Majem M
      – PersonEntity:
          Name:
            NameFull: Zhou C
      – PersonEntity:
          Name:
            NameFull: Tang KJ
      – PersonEntity:
          Name:
            NameFull: Kim SW
      – PersonEntity:
          Name:
            NameFull: Richardson G
      – PersonEntity:
          Name:
            NameFull: Girard N
      – PersonEntity:
          Name:
            NameFull: Sanborn RE
      – PersonEntity:
          Name:
            NameFull: Mansfield AS
      – PersonEntity:
          Name:
            NameFull: Park K
      – PersonEntity:
          Name:
            NameFull: Schuchard J
      – PersonEntity:
          Name:
            NameFull: Diels J
      – PersonEntity:
          Name:
            NameFull: Sermon J
      – PersonEntity:
          Name:
            NameFull: Bhattacharya A
      – PersonEntity:
          Name:
            NameFull: Lorenzini P
      – PersonEntity:
          Name:
            NameFull: Wortman-Vayn H
      – PersonEntity:
          Name:
            NameFull: Knoblauch RE
      – PersonEntity:
          Name:
            NameFull: Agrawal T
      – PersonEntity:
          Name:
            NameFull: Baig M
      – PersonEntity:
          Name:
            NameFull: Ono A
      – PersonEntity:
          Name:
            NameFull: Sabari JK
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2026 Mar
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1872-8332
          Numbering:
            – Type: volume
              Value: 213
          Titles:
            – TitleFull: Lung cancer (Amsterdam, Netherlands)
              Type: main
ResultId 1